Literatur

Früherkennung und Screening


Genetisches Risiko

2 Bundesärztekammer. Richtlinien zur Diagnostik der genetischen Disposition für Krebskrankungen. Dt Arztebl 1998; 95,A1396–1403
10 German Consortium for Hereditary Breast and Ovarian Cancer (Meindl A). Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002; 97:472–480

**Diagnostik**

5 DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997; 65(3):408–14


Pathologische Diagnostik

1 Scully RE. World Health Organization International Histological Classification of Tumours – Histological Typing of Ovarian Tumours. Springer, Berlin 1999

2 Tavassoli FA, Devilee P (Eds). World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon 2003


**Prognosefaktoren des Ovarialkarzinoms**


18 O’Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001; 83:334–42


Fruhes Ovarialkarzinom (FIGO I–IIA): Prognose und operative Therapie


Frühes Ovarialkarzinom (FIGO I–IIA): Adjuvante Therapie


Fortgeschrittenes Ovarialkarzinom (FIGO IIB–IV):
Prognose und operative Therapie

5 Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007; 104:480–490
6 Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 2006; 103:1070–1076
10 Chi DS, Eisenhauer EL, Lang J et al. What is optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006; 103:559–564
18. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997; 64:4–8

Fortgeschrittenes Ovarialkarzinom (FIGO IIB–IV):
Primäre Chemotherapie

8 The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360:505–15


Erhaltungstherapie


Ovarialkarzinomrezidiv: Operative Therapie


Ovarialkarzinomrezidiv: Systemische Therapie


7 Rose PG, Blessing JA, Mayer AR. Prolonged oral etoposide as second line therapy for platinum resistant (platr) and platinum sensitive (plats) ovarian carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 1997; (abstr 1297) 15:282


26 Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36:207–211


33 Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. Carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a gynaecologic cancer intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc Am Soc Clin Oncol 2004; (abstr. 5005):23

Psychoonkologie


Unkonventionelle Heilmethoden beim Ovarialkarzinom

1 American Cancer Society. American Cancer Society’s guide to complementary and alternative cancer methods. Atlanta, Georgia (American Cancer Society) 2000

15 Münstedt K. Ratgeber unkonventionelle Krebstherapie. Ecomed, Landsberg 2003
Nachsorge und Rehabilitation

1 Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften AWMF. Interdisziplinäre kurz gefasste Leitlinien der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe. Maligne Ovarialtumoren. 2001; AWMF-Leitlinien Register Nr. 032/035
11 Guppy A, Rustin G. CA125 Response: Can it replace the traditional response criteria in ovarian cancer? The Oncologist 2002; 7:437–443
Palliativmedizin


Borderline-Tumoren des Ovars

5 Donnez J, Munschke A, Berliere M et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertility and Sterility 2003; 79:1216–1221
26 Trimble CL, Kosary C, Trimble EL. Long-Term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002; 86:34–37
40 Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3:349–358
45 Seidman JD, Kurman RJ. Ovarian serous borderline tumors: A critical review with emphasis on prognostic indicators. Hum Pathol 2000; 31:539–557
Seidman JD, Soslow RA, Vang R et al. Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 2004; 35:918–933

Tavassoli FA, Devilee P (Eds): World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon 2003

**Maligne Keimzelltumoren**


46 Göbel U, Calaminus G, Koch S, Harms D, Schneider DT, Engert J. Is a watch and wait treatment possible in all malignant ovarian germ cell tumors (MOGCTs) FIGO 1? Results of the Cooperative MAKEI-Trials MPO 2003; 41,4:262 (Abstract)


**Keimstrangstroma-Tumoren des Ovars**


11 Pecorelli S, Wagenaar HC, Vergote I et al. Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa (-theca) cell tumors of the ovary. An EORTC Gynecological Cancer Cooperative Group Study. Eur J Cancer 1999; 35:1331–1337
19 Wang PH, Chao HT, Liu RS, Cho YH, Ng HT, Yuan CC. Diagnosis and localization of testosterone-producing tumors: imaging or biochemical evaluation. Gynecol Oncol 2001; 83:596–598